Carisma Therapeutics, Inc. (NASDAQ:CARM) Sees Large Decrease in Short Interest

Carisma Therapeutics, Inc. (NASDAQ:CARM) was the recipient of a large decrease in short interest in October. As of October 31st, there was short interest totalling 857,500 shares, a decrease of 18.3% from the October 15th total of 1,050,000 shares. Currently, 4.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 146,200 shares, the short-interest ratio is presently 5.9 days.

Wall Street Analysts Forecast Growth

Separately, EF Hutton Acquisition Co. I upgraded shares of Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CARM. Barclays PLC grew its holdings in shares of Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after acquiring an additional 549,290 shares during the last quarter. Wexford Capital LP increased its stake in Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Carisma Therapeutics during the 2nd quarter worth about $40,000. Finally, Vanguard Group Inc. lifted its stake in Carisma Therapeutics by 0.7% during the first quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock valued at $3,587,000 after buying an additional 11,200 shares in the last quarter. Institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Trading Down 5.9 %

CARM stock traded down $0.06 during trading hours on Friday, hitting $0.88. 238,783 shares of the stock traded hands, compared to its average volume of 184,739. The stock has a 50-day simple moving average of $0.98 and a 200 day simple moving average of $1.13. Carisma Therapeutics has a one year low of $0.80 and a one year high of $3.16. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39.

Carisma Therapeutics (NASDAQ:CARM) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) earnings per share for the quarter, meeting the consensus estimate of ($0.31). Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. The company had revenue of $3.39 million during the quarter. On average, equities research analysts expect that Carisma Therapeutics will post -1.33 EPS for the current fiscal year.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.